AKT1 and colorectal carcinoma: Using these novel clinical implications of dual activation of FOXO3a and β-catenin, the concurrent inhibition of both AKT and the Wnt/β-catenin pathway inhibitors suggests inducing apoptosis in cases of CRC patients’ poor clinical responses.